JP2023521667A5 - - Google Patents
Info
- Publication number
- JP2023521667A5 JP2023521667A5 JP2022560294A JP2022560294A JP2023521667A5 JP 2023521667 A5 JP2023521667 A5 JP 2023521667A5 JP 2022560294 A JP2022560294 A JP 2022560294A JP 2022560294 A JP2022560294 A JP 2022560294A JP 2023521667 A5 JP2023521667 A5 JP 2023521667A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- subject
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026011981A JP2026086494A (ja) | 2020-04-04 | 2026-01-28 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005251P | 2020-04-04 | 2020-04-04 | |
| US63/005,251 | 2020-04-04 | ||
| US202063037838P | 2020-06-11 | 2020-06-11 | |
| US63/037,838 | 2020-06-11 | ||
| US202063086921P | 2020-10-02 | 2020-10-02 | |
| US63/086,921 | 2020-10-02 | ||
| PCT/US2021/025495 WO2021202948A2 (en) | 2020-04-04 | 2021-04-02 | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026011981A Division JP2026086494A (ja) | 2020-04-04 | 2026-01-28 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521667A JP2023521667A (ja) | 2023-05-25 |
| JP2023521667A5 true JP2023521667A5 (cg-RX-API-DMAC7.html) | 2024-04-10 |
Family
ID=75625685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560294A Pending JP2023521667A (ja) | 2020-04-04 | 2021-04-02 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
| JP2026011981A Pending JP2026086494A (ja) | 2020-04-04 | 2026-01-28 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026011981A Pending JP2026086494A (ja) | 2020-04-04 | 2026-01-28 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230174674A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126219A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023521667A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202948A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| ES2905545T3 (es) * | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) * | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| EP4234583A3 (en) * | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| DK2946206T3 (en) * | 2013-01-20 | 2019-04-15 | Dyax Corp | EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS |
| JP2016513682A (ja) * | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| CN105873951A (zh) * | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
| CN110658337B (zh) * | 2013-10-21 | 2023-06-16 | 武田药品工业株式会社 | 自身免疫性疾病的诊断和治疗 |
| ES3065185T3 (en) * | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL247942B (en) * | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| IL314752A (en) * | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
-
2021
- 2021-04-02 WO PCT/US2021/025495 patent/WO2021202948A2/en not_active Ceased
- 2021-04-02 US US17/916,621 patent/US20230174674A1/en active Pending
- 2021-04-02 EP EP21720656.4A patent/EP4126219A2/en active Pending
- 2021-04-02 JP JP2022560294A patent/JP2023521667A/ja active Pending
-
2026
- 2026-01-28 JP JP2026011981A patent/JP2026086494A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241913B (en) | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C | |
| US7531164B2 (en) | Preventing bacterial or viral infectivity and composition containing infection preventing additive | |
| TW200528104A (en) | Combination therapy for hcv infection | |
| CN106535895A (zh) | 丁型肝炎病毒感染的治疗 | |
| WO2022039619A1 (ru) | Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2) | |
| JP2007501806A (ja) | ウィルス感染を治療する方法 | |
| JP2016153402A (ja) | C型肝炎ウイルス感染症の新規治療 | |
| CN118873497A (zh) | 盐酸米托蒽醌脂质体在治疗乳腺癌中的用途 | |
| Afdhal et al. | FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA: LB-3 | |
| Lawitz et al. | 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| CN117442704A (zh) | 一种治疗前列腺癌的药物组合及其应用 | |
| JP2024505482A (ja) | Cd73を上方調節することができる薬剤及びグルココルチコイドの順次投与による疾患の治療 | |
| WO2021246989A1 (en) | A combination of camostat mesylate and umifenovir hydrochloride | |
| JP2014509628A (ja) | C型肝炎ウイルス感染症を治療するためのアリスポリビル | |
| CA2614639C (en) | Pharmaceutical composition for treatment of blood clotting disorder | |
| Leav et al. | Safety and pharmacokinetics of a novel human monoclonal antibody directed against the E2 glycoprotein of hepatitis C virus (MBL-HCV1) in healthy volunteers | |
| US20160184446A1 (en) | Method of inhibiting body cavity fluid accumulation | |
| Hoque | Literature review of prospective drugs for COVID-19 | |
| US20230210890A1 (en) | Compositions and methods of treating covid-19 with heparin or other negatively charged molecules | |
| HK40104643A (en) | Treatment of diseases with sequential administration of an agent capable of up-regulating cd73 and glucocorticoids | |
| TW201110976A (en) | Medicinal agent and method for treatment of intractable chronic hepatitis c | |
| JP2001516725A (ja) | 慢性C型肝炎症の処置のためのIFN−αとアマンタジンの使用 | |
| Rabe et al. | Benefits of tiotropium/olodaterol over tiotropium alone in delaying clinically significant deterioration in patients with COPD | |
| WO2025209478A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib |